OPtical frequency domain imaging vs. INtravascular ultrasound in percutaneous coronary InterventiON in patients with Acute Coronary Syndrome: Study protocol for a randomized controlled trial.


Journal

Journal of cardiology
ISSN: 1876-4738
Titre abrégé: J Cardiol
Pays: Netherlands
ID NLM: 8804703

Informations de publication

Date de publication:
09 2020
Historique:
received: 17 02 2020
revised: 17 03 2020
accepted: 22 03 2020
pubmed: 29 4 2020
medline: 18 5 2021
entrez: 29 4 2020
Statut: ppublish

Résumé

A recent clinical trial demonstrated that optical frequency domain imaging (OFDI) guidance in percutaneous coronary intervention (PCI) is noninferior to intravascular ultrasound (IVUS) guidance in patients with coronary artery disease with regard to target vessel failure (composed of cardiac death, myocardial infarction attributed to the target vessel, and clinically-driven target vessel revascularization) at 12 months. The impact of OFDI guidance in PCI for patients with acute coronary syndrome (ACS) remains uncertain. OPINION ACS is a multicenter, prospective, randomized, controlled, open-label, parallel group, non-inferiority trial in Japan. Eligible patients will be randomly assigned to receive either OFDI- or IVUS-guided PCI. PCI is performed using the sirolimus-eluting stent in accordance with certain OFDI and IVUS criteria for optimal stent deployment. All patients will undergo follow-up angiography and OFDI imaging at 8 months. The primary endpoint is the minimum lumen area, as measured by OFDI at 8 months. The OPINION ACS trial outcomes will provide insights regarding the impact of OFDI-guided PCI on in-stent restenosis at 8 months in patients with ACS.

Sections du résumé

BACKGROUND
A recent clinical trial demonstrated that optical frequency domain imaging (OFDI) guidance in percutaneous coronary intervention (PCI) is noninferior to intravascular ultrasound (IVUS) guidance in patients with coronary artery disease with regard to target vessel failure (composed of cardiac death, myocardial infarction attributed to the target vessel, and clinically-driven target vessel revascularization) at 12 months. The impact of OFDI guidance in PCI for patients with acute coronary syndrome (ACS) remains uncertain.
METHODS
OPINION ACS is a multicenter, prospective, randomized, controlled, open-label, parallel group, non-inferiority trial in Japan. Eligible patients will be randomly assigned to receive either OFDI- or IVUS-guided PCI. PCI is performed using the sirolimus-eluting stent in accordance with certain OFDI and IVUS criteria for optimal stent deployment. All patients will undergo follow-up angiography and OFDI imaging at 8 months. The primary endpoint is the minimum lumen area, as measured by OFDI at 8 months.
CONCLUSION
The OPINION ACS trial outcomes will provide insights regarding the impact of OFDI-guided PCI on in-stent restenosis at 8 months in patients with ACS.

Identifiants

pubmed: 32340781
pii: S0914-5087(20)30123-4
doi: 10.1016/j.jjcc.2020.03.010
pii:
doi:

Substances chimiques

Sirolimus W36ZG6FT64

Types de publication

Clinical Trial Protocol Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

317-321

Informations de copyright

Copyright © 2020 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Auteurs

Hiromasa Otake (H)

Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan. Electronic address: hotake@med.kobe-u.ac.jp.

Takashi Kubo (T)

Department of Cardiovascular Medicine, Wakayama Medical University, Wakayama, Japan.

Toshiro Shinke (T)

Division of Cardiology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.

Kiyoshi Hibi (K)

Division of Cardiology, Yokohama City University Medical Center, Yokohama, Japan.

Shigemitsu Tanaka (S)

Division of Cardiology, Tokai University School of Medicine, Isehara, Japan.

Masaru Ishida (M)

Division of Cardiology, Iwate Medical University, Yahaba-cho, Japan.

Toru Kataoka (T)

Division of Cardiology, Bell Land General Hospital, Sakai, Japan.

Tomofumi Takaya (T)

Division of Cardiovascular Medicine, Hyogo Prefectural Himeji Cardiovascular Center, Himeji, Hyogo, Japan.

Masamichi Iwasaki (M)

Department of Cardiology, Hyogo Prefectural Awaji Medical Center, Sumoto, Hyogo, Japan.

Shinjo Sonoda (S)

The Second Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.

Tetsuya Ioji (T)

Division of Medical Statistics, Translational Research Center for Medical Innovation, Kobe, Japan.

Takashi Akasaka (T)

Department of Cardiovascular Medicine, Wakayama Medical University, Wakayama, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH